Diabetes Drugmaker

The venture, called Onduo, will initially focus on type two diabetes, the more common form of the disease.

French drugmaker Sanofi and Google owner Alphabet's U.S-based life sciences company Verily, announced on Monday the launch of a joint-venture aimed at offering patients suffering from diabetes products that will combine devices and services.

India's fourth-largest drugmaker by sales will buy privately-held firms InvaGen Pharmaceuticals Inc and Exelan Pharmaceuticals Inc, gaining multiple products in the areas of anti-infectives, diabetes and central nervous system disorders.

Swiss drugmaker Novartis has struck an agreement with Google to develop "smart" contact lenses that would help diabetics track their blood glucose levels or restore the eye's ability to focus.

India's pharmaceutical pricing regulator has cut and capped the prices of more than 100 drugs used to treat diseases ranging from diabetes to HIV to malaria, a move likely to hit the profit margins of drug firms like Sanofi SA, Abbott Laboratories and Ranbaxy Laboratories Ltd.

Novartis has taken Biocon to court for infringing the patent on its diabetes drug Galvus, the Swiss drugmaker said in a statement on Thursday.

Cadila, India's sixth-largest drugmaker by sales, spent $250 million developing Lipaglyn, a new chemical entity or new discovery, and aims to spend another $150 million to $200 million to launch the drug outside India, the company's chairman, Pankaj Patel, said.

In the fall of 1999, the drug giant SmithKline Beecham secretly began a study to find out if its diabetes medicine, Avandia, was safer for the heart than a competing pill, Actos, made by Takeda. Avandia's success was crucial to SmithKline, whose labs were otherwise all but barren of new products. But the study's results, completed that same year, w...

The venture, called Onduo, will initially focus on type two diabetes, the more common form of the disease.

French drugmaker Sanofi and Google owner Alphabet's U.S-based life sciences company Verily, announced on Monday the launch of a joint-venture aimed at offering patients suffering from diabetes products that will combine devices and services.

India's fourth-largest drugmaker by sales will buy privately-held firms InvaGen Pharmaceuticals Inc and Exelan Pharmaceuticals Inc, gaining multiple products in the areas of anti-infectives, diabetes and central nervous system disorders.

Swiss drugmaker Novartis has struck an agreement with Google to develop "smart" contact lenses that would help diabetics track their blood glucose levels or restore the eye's ability to focus.

India's pharmaceutical pricing regulator has cut and capped the prices of more than 100 drugs used to treat diseases ranging from diabetes to HIV to malaria, a move likely to hit the profit margins of drug firms like Sanofi SA, Abbott Laboratories and Ranbaxy Laboratories Ltd.

Novartis has taken Biocon to court for infringing the patent on its diabetes drug Galvus, the Swiss drugmaker said in a statement on Thursday.

Cadila, India's sixth-largest drugmaker by sales, spent $250 million developing Lipaglyn, a new chemical entity or new discovery, and aims to spend another $150 million to $200 million to launch the drug outside India, the company's chairman, Pankaj Patel, said.

In the fall of 1999, the drug giant SmithKline Beecham secretly began a study to find out if its diabetes medicine, Avandia, was safer for the heart than a competing pill, Actos, made by Takeda. Avandia's success was crucial to SmithKline, whose labs were otherwise all but barren of new products. But the study's results, completed that same year, w...